Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by indaknownewfieon Aug 08, 2019 5:12pm

76 Views

Post# 30008556

RE:RE:Graft Versus Host Disease

Couldnt agree more. That's precisely the point I was trying to make. They are looking at Ruxolitnib and seven other drugs which are BAT (best available treatment) but none of them come close to the success that Kalytera has already achieved with our patented CBD. This is a gold mine in the making, especially at these levels when you can load up. Im long on this for close to three years. Go Kaly.

Bullboard Posts

A junior copper-gold stock trading at a bargain of monumental proportions